

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<https://repository.ubn.ru.nl/handle/2066/238211>

Please be advised that this information was generated on 2021-11-02 and may be subject to change.



# Editorial: Online Adaptive MR-Guided Radiotherapy

Linda G. W. Kerkmeijer<sup>1\*</sup>, Vincenzo Valentini<sup>2</sup>, Clifton D. (Dave) Fuller<sup>3</sup> and Ben J. Slotman<sup>4</sup>

<sup>1</sup> Department of Radiation Oncology, Radboudumc, Nijmegen, Netherlands, <sup>2</sup> Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome, Italy, <sup>3</sup> Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, United States, <sup>4</sup> Department of Radiation Oncology, Amsterdam UMC, Amsterdam, Netherlands

**Keywords:** MRI, external beam radiotherapy, MR-guided radiotherapy, adaptive, image-guided radiotherapy

## Editorial on the Research Topic

### Online Adaptive MR-Guided Radiotherapy

The radiotherapy field is rapidly evolving due to advances in radiation delivery and image guidance. After the introduction of image guided radiotherapy (IGRT) two decades ago, the integration of magnetic resonance imaging (MRI) with linear accelerators is the next logic step in IGRT. MR-guided radiotherapy will lead to a paradigm shift in radiation oncology for multiple clinical indications in the head and neck, thorax, abdomen and pelvis and opens new opportunities to increase precision and to adapt the treatment (1–3).

In this Research Topic, the opportunities and challenges when using online adaptive MR-guided radiotherapy will be described. Online adaptive magnetic resonance guided radiotherapy (MRgRT) has the potential to improve both oncologic outcomes due to dose escalation and ultra-hypofractionation, and decrease toxicity due to improved targeting accuracy by inter- and intrafraction adaptation. However, the adaptive workflow is also time and resource intensive and requires a drastic transformation of the offline and online radiotherapy workflow (4, 5).

Two MRI linear accelerator (MR-linac) systems to deliver MRgRT are commercially available and have been clinically implemented across the world, other systems are being developed. The technical specifications, opportunities and challenges of these MRgRT platforms (Elekta Unity and Viewray MRIdian) are described by Thorwarth and Low. In order to reduce time and resources per treatment fraction, automatization of most of the realtime MRgRT workflow is necessary. Before routine implementation of these technical solutions, large standardized data sets including both clinical and technical data are required for training and clinical validation of these models.

Although differences across both platforms are present and for few indications one system may have advantages over the other, in general, both systems offer new functionality, including MR-guidance and online adaptation when compared to conventional CT-guided radiotherapy. With increasing implementation of MRgRT systems, the time window for high quality comparative (randomized) trials is narrow, as described by Verkooijen and Henke. International collaborative studies, preferably across platforms, are warranted to gain this timely evidence of the superiority of MRgRT including patient-reported endpoints. For both systems, international research consortia have been formed, where expert clinicians, physicists, methodologists, therapists and technologists join forces for an evidence-based introduction of the technology and optimize the clinical impact (6). Large international prospective data registries collecting clinical and technical data are being

## OPEN ACCESS

### Edited and reviewed by:

Timothy James Kinsella,  
Warren Alpert Medical School of  
Brown University, United States

### \*Correspondence:

Linda G. W. Kerkmeijer  
linda.kerkmeijer@radboudumc.nl

### Specialty section:

This article was submitted to  
Radiation Oncology,  
a section of the journal  
Frontiers in Oncology

**Received:** 28 July 2021

**Accepted:** 11 August 2021

**Published:** 30 August 2021

### Citation:

Kerkmeijer LGW, Valentini V,  
Fuller CD and Slotman BJ (2021)  
Editorial: Online Adaptive  
MR-Guided Radiotherapy.  
Front. Oncol. 11:748685.  
doi: 10.3389/fonc.2021.748685

set-up aiming to include all patients treated at the MR-linac for an evidence-based introduction of the technology and further evolution of the technology (7).

When introducing complex innovations in radiation oncology, a randomized controlled trial will not be the first step after clinical implementation of the novel technology. Several preparatory steps are required before comparative studies can be initiated, especially with a continuously evolving technology and evolving clinical application. The R-IDEAL framework describes the steps towards an evidence-based introduction of the new technology, with Phase 0 (Radiotherapy predicate studies), Phase 1 (Idea, first in man study), Phase 2a (technical development studies), Phase 2b (Exploration, early effectiveness in randomized studies), Phase 3 (Assessment in comparative studies) followed by Phase 4 (Long-term results) (8). Furthermore early Health Technology Assessments of resource-intensive treatments would help facilitate the reimbursement policy.

Besides the online adaptive approach and MR-guidance during treatment, one of the unique aspects of MRgRT, is the opportunity to perform biology-based image guided adaptive radiotherapy (BIGART) as described by Van Houdt et al. By acquiring biological images revealing metabolic and functional data, focal dose escalation to the gross tumor volume within the clinical target volume can be pursued, for example for prostate cancer (9). Also this opens opportunities for ‘dose painting by numbers’ within the tumor volume by using the heterogenic characteristics within the tumor to deposit a differentiated dose per voxel (10). MRgRT allows for daily quantitative imaging by visualizing the tumor volume, shape and biology before and during each radiotherapy fraction. Adaptation to changing tumor shape and volume is already possible in present-day MRgRT. In addition, imaging biomarkers need to be identified that can predict treatment response early in the course of treatment, which may eventually lead to response-adapted radiotherapy. Again, large multicenter (standardized) imaging and clinical data with multicenter and multiple tumor site validation are necessary, which further strengthens the importance of collaboration in large international data registries.

While BIGART may potentially impact all radiotherapy (+/- systemic therapy) applications, it may be of particular importance for the enhancement of radio-immunotherapy. The immunogenic effect of radiation and its synergy with immunotherapy, has been observed in several pre-clinical and clinical studies and in pre-clinical studies the dose per fraction seemed to be critical (11). As MRgRT allows for safe ultrahypofractionation and reduces the volume of normal tissue irradiated by reduced treatment margins, radio-immunotherapy delivered by MR-guidance may be a perfect match. Furthermore, MRgRT facilitates visualization of the anatomical sites that should or should not receive radiation, allowing for new clinical treatment paradigms such as partial tumor irradiation or draining lymph node sparing. Many questions need to be addressed such as radiation dose, fractionation, timing of radiotherapy versus immunotherapy, target volumes and biomarkers for response prediction as highlighted by Hörner-Rieber et al. It should not

be a surprise, that international collaboration, standardization and clinical and imaging data collection, including biomaterial, will be the driving force towards optimization of this combination treatment and proving its impact on oncological outcomes.

Since 2015, MR-linacs have been first used and were implemented across the world from initial users to now dozens of early adopters (12, 13). After the predicate and first in man studies, for several clinical indications studies have been performed on the early effectiveness, toxicity and patient reported outcomes of MRgRT. In this editorial, several review articles on MRgRT to treat tumors in the brain and spine, head and neck, lung, esophagus, pancreas, kidney, liver, cervix, prostate, bladder and rectum) are presented, including an overview of the current evidence, clinical experience, state of the art implementation of MR-guided radiotherapy and future perspectives (Boldrini et al.; Boeke et al.; Tocco et al.; Crockett et al.; Boldrini et al.; Maziero et al.; Lee et al.; Hall et al.; Keller et al.; Hijab et al.; Portelance et al.).

Although clinicians see the great potential of MRgRT as a logical next step in IGRT, and the first studies support the potential benefit of MRgRT, randomized clinical evidence is not yet available. A collaborative international effort (across platforms) to set up comparative trials or prospective registry studies will be necessary in the generation of high quality evidence on the benefits of MRgRT over CT-guided radiotherapy.

With this Research Topic on online adaptive MR-guided radiotherapy, we aim to give the reader an overview of the ongoing advances in MR-guided radiotherapy to facilitate institutes on the verge of implementation of MR-guided radiotherapy into clinical practice. We thank all authors for their excellent invited reviews and their willingness to collaborate across platforms and share their expertise on MR-guided radiotherapy. We believe that MR-guided radiotherapy can have a tremendous impact on outcomes for patients for multiple oncological indications. Advances in image-guided adaptive and response-based radiotherapy are expected to translate into improved oncologic outcomes, increasing the number of indications to be treated by stereotactic radiotherapy as a non-invasive treatment modality, reducing toxicity and reducing the impact of cancer treatment on quality of life. Therefore, we would like to make a ‘warm plea’ for international and across platforms collaboration of experts involved in the multidisciplinary teams of MR-guided radiotherapy to maximize the benefit of this paradigm shift in radiation oncology and to prove its superior outcome and cost-utility for the radiotherapeutic treatment of cancer patients rather sooner than later.

## AUTHOR CONTRIBUTIONS

All authors were involved in the conception and design of this editorial. LK drafted the manuscript. All authors contributed to the article and approved the submitted version.

## REFERENCES

- Hall WA, Paulson ES, van der Heide UA, Fuller CD, Raaymakers BW, Lagendijk JJW, et al. The Transformation of Radiation Oncology Using Real-Time Magnetic Resonance Guidance: A Review. *Eur J Cancer* (2019) 122:42–52. doi: 10.1016/j.ejca.2019.07.021
- Corradini S, Alongi F, Andratschke N, Azria D, Bohoudi O, Boldrini L, et al. ESTRO-ACROP Recommendations on the Clinical Implementation of Hybrid MR-Linac Systems in Radiation Oncology. *Radiother Oncol* (2021) 159:146–54. doi: 10.1016/j.radonc.2021.03.025
- Corradini S, Alongi F, Andratschke N, Belka C, Boldrini L, Cellini F, et al. MR-Guidance in Clinical Reality: Current Treatment Challenges and Future Perspectives. *Radiat Oncol* (2019) 14(1):92. doi: 10.1186/s13014-019-1308-y
- Green OL, Henke LE, Hugo GD. Practical Clinical Workflows for Online and Offline Adaptive Radiation Therapy. *Semin Radiat Oncol* (2019) 29(3):219–27. doi: 10.1016/j.semradi.2019.02.004
- Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. Adaptive Radiotherapy: The Elekta Unity MR-Linac Concept. *Clin Trans Radiat Oncol* (2019) 18:54–9. doi: 10.1016/j.ctro.2019.04.001
- Kerkmeijer LG, Fuller CD, Verkooijen HM, Verheij M, Choudhury A, Harrington KJ, et al. The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. *Front Oncol* (2016) 6:215. doi: 10.3389/fonc.2016.00215
- de Mol van Otterloo SR, Christodouleas JP, Blezer E, Akhlat H, Brown K, Choudhury A, et al. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. *Front Oncol* (2020) 10:1328. doi: 10.3389/fonc.2020.01328
- Verkooijen HM, Kerkmeijer L, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, et al. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. *Front Oncol* (2017) 7:59. doi: 10.3389/fonc.2017.00059
- Kerkmeijer LGW, Groen VH, Pos FJ, Hausermans K, Monninkhof EM, Smeenk RJ, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. *J Clin Oncol* (2021) 39(7):787–96. doi: 10.1200/JCO.20.02873
- Van Schie MA, Steenbergen P, Dinh CV, Ghobadi G, van Houdt PJ, Pos FJ, et al. Repeatability of Dose Painting by Numbers Treatment Planning in Prostate Cancer Radiotherapy Based on Multiparametric Magnetic Resonance Imaging. *Phys Med Biol* (2017) 62(14):5575–88. doi: 10.1088/1361-6560/aa75b8
- Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA Exonuclease Trex1 Regulates Radiotherapy-Induced Tumour Immunogenicity. *Nat Commun* (2017) 8:15618. doi: 10.1038/ncomms15618
- Raaymakers BW, Jürgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte ANTJ, van Asselen B, et al. First Patients Treated With a 1.5 T MRI-Linac: Clinical Proof of Concept of a High-Precision, High-Field MRI Guided Radiotherapy Treatment. *Phys Med Biol* (2017) 62(23):L41–50. doi: 10.1088/1361-6560/aa9517
- van Sörnsen de Koste JR, Palacios MA, Bruynzeel AME, Slotman BJ, Senan S, Lagerwaard FJ. MR-Guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis. *Int J Radiat Oncol Biol Phys* (2018) 102(4):858–66. doi: 10.1016/j.ijrobp.2018.05.048

**Conflict of Interest:** LK: The Radboudumc and UMC Utrecht are members of the MR-linac Consortium. Elekta financially supports the MR-linac Consortium and its member institutes in their research programs. VV: declares participation in a company sponsored speaker's bureau and receipt of grants/research supports: AMGEN, ASTELLAS, ASTRAZENeca, BAYER, BRISTOL MYERS SQUIBB, Eisai, Ferring, IPSEN, ISTITUTOGENTILI, JANSSEN-Cilag, MSD, Merck, Norgine, Novartis Farma, Pfizer, Roche, Sanofi, Servier Italia, Varian, Elekta, ViewRay. DF: has received federal funding and salary support unrelated to this project from the, including: the National Institutes of Health (NIH) National Institute for Dental and Craniofacial Research Establishing Outcome Measures Award (1R01DE025248/R56DE025248) and an Academic Industrial Partnership Grant (R01DE028290); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672) and an NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPOR) Developmental Research Program Award (P50 CA097007); National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBB) Grant (NSF 1557679); NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) standard grant (NSF 1933369) a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787-01); the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825). Direct infrastructure support is provided to Dr. Fuller by the philanthropic gift of the Stiefel Oropharyngeal Research Fund of the University of Texas MD Anderson Cancer Center Charles and Daneen Stiefel Center for Head and Neck Cancer, the Cancer Center Support Grant Radiation Oncology/Cancer Imaging Program and Multi-Investigator Research Program (both via P30CA016672), and the MD Anderson Program in Image-guided Cancer Therapy. DF has received direct industry grant support, honoraria, and travel funding from Elekta AB. BS: AmsterdamUMC has research grants for Varian medical systems and ViewRay. I have received honorarium from ViewRay.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kerkmeijer, Valentini, Fuller and Slotman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.